[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-chronic-inflammatory-demyelinating-polyneuropathy-cidp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-chronic-inflammatory-demyelinating-polyneuropathy-cidp":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100338251",false,"NCT03684018","Two Dose Levels of Privigen in Pediatric CIDP","Randomized Study of Two Dose Levels of Privigen in Pediatric CIDP","Inclusion Criteria:\n\n* \\- Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP.\n\nExclusion Criteria:\n\n* \\- Absence of CIDP symptoms\n* -History or family history of inherited neuropathy\n* -Diagnosed developmental delay or regression\n* -History of thrombotic episode\n* -Known or suspected hypersensitivity to Privigen\n* -Known allergic or other severe reactions to blood products\n* -Female subject of childbearing potential either not using or not willing to use a medically reliable method of contraception or not sexually abstinent during the study\n* -Pregnant or breastfeeding mother\"","ALL","2 Years","17 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment",[26],"Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","RECRUITING","2026-05-28",{"date":30,"type":31},"2026-06-01","ACTUAL",{"date":33,"type":31},"2019-02-28",{"date":35,"type":20},"2029-12-20",{"name":37,"class":38},"CSL Behring","INDUSTRY",9,""]